The Shifting Goalposts: Understanding the Delay in New EDS Diagnostic Criteria

The Ehlers-Danlos Society has officially recalibrated its timeline for the highly anticipated publication of new diagnostic criteria for hypermobile Ehlers-Danlos Syndrome (hEDS) and related monogenic types. Originally expected to culminate in a comprehensive, unified release, the organization’s “Road to 2026” initiative—published in the American Journal of Medical Genetics—has transitioned into a two-part rollout.

For the vast, global community of patients, clinicians, and researchers, this news marks a period of redirected expectations. While the scientific rigor required for such a fundamental shift in medical classification is immense, the delay underscores the profound complexities inherent in defining a multisystemic, poorly understood condition.

The Revised Chronology: A Two-Phase Rollout

The EDS Society confirmed that the updated diagnostic framework will no longer appear as a single, consolidated document. Instead, the publication schedule has been bifurcated to accommodate the breadth of the research:

  • Part 1 (December 2, 2026): This initial release will focus primarily on the monogenic (rare) types of Ehlers-Danlos, providing updated clinical guidelines for those specific genetic variants.
  • Part 2 (March/April 2027): This subsequent publication will feature the revised diagnostic criteria for hEDS and the broader spectrum of hypermobility-related disorders.

This shift in the publication calendar, while necessary for editorial and scientific reasons, has caused a palpable ripple of frustration through a patient population that has spent months following a highly branded, high-stakes countdown.

Official Responses and Scientific Rationale

Dr. Clair Francomano, a leading voice in the field, has sought to temper the anxiety caused by the delay. Addressing the logistical realities of the publication, she noted that the volume of data simply exceeded the capacity of a single journal edition.

"There was always too much to put into one publication, so the decision was made to focus on the monogenic types in the first edition," Dr. Francomano explained. "I hate that this has caused more anxiety for patients, but science is evolving quickly and we want to get this right."

Crucially, the Society has moved to reassure current patients that their status is secure. A primary fear among those already diagnosed is that new, more stringent, or altered criteria could effectively invalidate their existing medical records. The Society has explicitly stated that nobody is going to lose their diagnosis. Clinicians are encouraged to continue utilizing the 2017 criteria until the new, refined standards are formally adopted in the spring of 2027.

The Divergent Hopes of the Community

The urgency surrounding these criteria is not uniform. The EDS community is not a monolith; rather, it is a coalition of distinct groups, each with unique grievances and hopes for the upcoming classification changes.

The hEDS Perspective: Beyond Hypermobility

For those living with hEDS, the primary criticism of the 2017 criteria is that they are "too narrow." By focusing almost exclusively on joint hypermobility, the current standards fail to capture the multi-systemic reality of the condition. Patients frequently suffer from systemic comorbidities—including dysautonomia, gastroparesis, and complex neurological issues—that are often ignored or treated in isolation.

Jon Rodis, founder of The Connective Tissue Coalition, advocates for a criteria set that reflects this clinical reality. "It is imperative that the new criteria address the many comorbid conditions that are part of hEDS and are backed up by high-level research and the valuable patient perspective," Rodis asserts. He notes that the current model leaves many patients without a path to effective, holistic care.

The HSD Crisis: Seeking Equity

The 2017 introduction of the Hypermobility Spectrum Disorder (HSD) label was intended to capture those who did not meet the rigid hEDS criteria but were still symptomatic. However, in practice, HSD has often functioned as a "lesser" label, leading to systemic clinical neglect.

In many healthcare systems, particularly in Europe, an HSD diagnosis acts as a barrier to receiving specialized care or insurance coverage. The conversation now leans toward the potential for "blending" hEDS and HSD into a more inclusive spectrum, acknowledging that the clinical severity of an HSD patient can be identical to that of an hEDS patient.

What’s Actually Happening With the New EDS Diagnostic Criteria?

The "Orphaned" Rare Types

The most radical call for change comes from the rare and monogenic types of EDS (such as Vascular, Classical, and Kyphoscoliotic EDS). Abbey Phillipson, a founder of The Collagen Advocacy Network, has argued that these groups are being underserved by the current "umbrella" classification.

Because these conditions have clear genetic markers, they often require different medical protocols than hEDS. Phillipson’s advocacy highlights a systemic problem: when rare patients are grouped under the same diagnostic header as hEDS, clinicians often apply a "one-size-fits-all" approach that can lead to misdiagnosis and dangerous medical errors. The goal for this group is distinct nomenclature—essentially separating the rare types from the umbrella to ensure they receive appropriate, high-stakes care and research funding.

Emerging Frameworks: The Case for "Neuro-EDS"

As the community awaits the formal criteria, a compelling new framework has emerged: "Neuro-EDS." Introduced by neurosurgeon Dr. Paolo Bolognese and Dr. Allison Bloom, this concept was presented at the 2026 EDS Society Conference in Texas.

It is critical to note that Neuro-EDS is not a new disease or a new EDS type. Instead, it is a proposed phenotypic classification. It seeks to identify a subgroup of hEDS and HSD patients whose primary burden of illness is neurological. By grouping patients based on the body systems most affected rather than just joint laxity, the proponents argue that clinicians can better tailor treatments for conditions like craniocervical instability.

For patients who have been repeatedly gaslit by the medical establishment and labeled as having "psychosomatic" symptoms, this framework offers a potential lifeline. German advocate Karina Sturm notes that for patients in regions where specialized care is sparse, a neurological classification could provide the clinical validation necessary to access surgeries and treatments that are currently denied to them.

Implications for the Future of Care

The delay in publication is more than a scheduling issue; it is a symptom of the "herculean task" of classifying a complex, multi-systemic disease. The process of peer review, while slow, is the final line of defense against pseudoscience.

As we look toward the spring of 2027, the stakes remain high. The medical community is balancing the need for:

  1. Clinical Rigor: Ensuring that every diagnostic criterion is backed by high-level genetic and physiological research.
  2. Patient Utility: Ensuring that the criteria are not just scientifically accurate, but clinically useful in the day-to-day management of symptoms.
  3. Safety: Protecting those with rare, life-threatening genetic variants from the consequences of misclassification.

For the patient in the waiting room—the one struggling with digestive failures, neurological instability, or the fear that their life-altering symptoms will be dismissed—the wait for March 2027 feels like an eternity. However, the movement toward a more nuanced, systemic, and accurate classification system suggests that the future of EDS care may finally be moving toward a model that sees the patient, not just the joint.

The promise of these upcoming papers is that they will move the community away from the "narrow" focus of 2017 and toward a more integrated, evidence-based understanding of human connective tissue. Until then, the community continues its advocacy, pushing for a future where a diagnosis is not a barrier to care, but a bridge to health.


Written by DM Sullivan, Producer, Complicated, and Founder & Executive Director of Elevate Rare. November 2026.

Sources:

  • Forghani I, See J, McGonigle WC. “Hypermobile Ehlers–Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.” Genes (Basel). 2025 Apr 29;16(5):530.
  • Bolognese P, Bloom A, et al. “Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders.” Preprints.org, 2026.
  • The Ehlers-Danlos Society, "The Road to 2026" Official Updates, 2026.

More From Author

The Clockwork Body: Why Daily Consistency Is the Secret to Longevity and Mental Well-being